Insmed Inc INSM

NAS: INSM | ISIN: US4576693075   7/11/2025
189,70 USD (+2,17%)
(+2,17%)   7/11/2025

5 november 2025 · Insmed To Present at November and December 2025 Investor Conferences · Persbericht

30 oktober 2025 · Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update · Persbericht

23 oktober 2025 · Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List · Persbericht

17 oktober 2025 · CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis · Persbericht

16 oktober 2025 · Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025 · Persbericht

15 oktober 2025 · Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025 · Persbericht

22 september 2025 · Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025 · Persbericht

5 september 2025 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

21 augustus 2025 · Insmed To Present at September Investor Conferences · Persbericht

12 augustus 2025 · FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease · Persbericht

7 augustus 2025 · Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update · Persbericht

4 augustus 2025 · Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas · Persbericht

24 juli 2025 · Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025 · Persbericht

12 juni 2025 · Insmed Announces Pricing of $750 Million Public Offering of Common Stock · Persbericht

11 juni 2025 · Insmed Announces Proposed $650 Million Public Offering of Common Stock · Persbericht

10 juni 2025 · Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension · Persbericht

4 juni 2025 · Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

28 mei 2025 · Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference · Persbericht

21 mei 2025 · Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study · Persbericht

8 mei 2025 · Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update · Persbericht

Mijn selecties